Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)
Harter, Philipp, Sehouli, Jalid, Kimmig, Rainer, Rau, Jörn, Hilpert, Felix, Kurzeder, Christian, Elser, Gabriele, Bois, AndreasVolume:
31
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-013-0011-3
Date:
December, 2013
File:
PDF, 162 KB
english, 2013